{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T03:59:04Z","timestamp":1776916744640,"version":"3.51.2"},"reference-count":39,"publisher":"Bentham Science Publishers Ltd.","issue":"1","funder":[{"DOI":"10.13039\/501100013093","name":"Forefront International, research fund of UF\/Health Cancer Center and research funds from Science and Technology Planning Technical Research Project of Shenzhen, China","doi-asserted-by":"publisher","award":["KQTD2014063014 3254906"],"award-info":[{"award-number":["KQTD2014063014 3254906"]}],"id":[{"id":"10.13039\/501100013093","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013093","name":"Forefront International, research fund of UF\/Health Cancer Center and research funds from Science and Technology Planning Technical Research Project of Shenzhen, China","doi-asserted-by":"publisher","award":["JCYJ20160229170523065"],"award-info":[{"award-number":["JCYJ20160229170523065"]}],"id":[{"id":"10.13039\/501100013093","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013093","name":"Forefront International, research fund of UF\/Health Cancer Center and research funds from Science and Technology Planning Technical Research Project of Shenzhen, China","doi-asserted-by":"publisher","award":["JCYJ2017041315 4349187"],"award-info":[{"award-number":["JCYJ2017041315 4349187"]}],"id":[{"id":"10.13039\/501100013093","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005408","name":"UESTC","doi-asserted-by":"publisher","award":["ZYGX2016Z009"],"award-info":[{"award-number":["ZYGX2016Z009"]}],"id":[{"id":"10.13039\/501100005408","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005408","name":"UESTC","doi-asserted-by":"publisher","award":["SQ2016YFS F090567"],"award-info":[{"award-number":["SQ2016YFS F090567"]}],"id":[{"id":"10.13039\/501100005408","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CGT"],"published-print":{"date-parts":[[2019,5,28]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p>&lt;P&gt;Introduction: Recent studies on CD19-specific chimeric antigen receptor (CAR)-modified\nT cells (CARTs) have demonstrated unprecedented successes in treating refractory and relapsed B cell\nmalignancies. The key to the latest CART therapy advances can be attributed to the improved\ncostimulatory signals in the CAR design.\n&lt;\/P&gt;&lt;P&gt;\nMethods: Here, we established several novel CARs by incorporating T cell signaling domains of\nCD28 in conjunction with intracellular signaling motif of 4-1BB, CD27, OX40, ICOS, and IL-15R\u03b1.\nThese novel CARs were functionally assessed based on a simple target cell killing assay.\n&lt;\/P&gt;&lt;P&gt;\nResults: The results showed that the CD28\/IL-15R&amp;#945; co-signaling (153z) CAR demonstrated the fastest\nT cell expansion potential and cytotoxic activities. IL-15 is a key cytokine that mediates immune\neffector activities. The 153z CARTs maintained prolonged killing activities after repetitive rounds of\ntarget cell engagement. Consistent with the enhanced target killing function, the 153z CARTs produced\nincreased amount of effector cytokines including IFN-&amp;#947;, TNF&amp;#945; and IL-2 upon interaction with\nthe target cells.\n&lt;\/P&gt;&lt;P&gt;\nConclusion: In a follow-up clinical study, an acute lymphoblastic leukemia (ALL) patient, who experienced\nmultiple relapses of central nervous system leukemia (CNSL) and failed all conventional\ntherapies, was enrolled to receive the CD19-specific 153z CART treatment. The patient achieved\ncomplete remission after the 153z CART cell infusion. The translational outcome supports further investigation\ninto the safety and enhanced therapeutic efficacy of the IL-15R\u03b1-modified CART cells in\ncancer patients.&lt;\/P&gt;<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1566523218666181116093857","type":"journal-article","created":{"date-parts":[[2018,11,16]],"date-time":"2018-11-16T06:02:29Z","timestamp":1542348149000},"page":"40-53","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Functional Improvement of Chimeric Antigen Receptor Through Intrinsic Interleukin-15R\u03b1 Signaling"],"prefix":"10.2174","volume":"19","author":[{"given":"Sushmita","family":"Nair","sequence":"first","affiliation":[{"name":"Department of Molecular Genetics and Microbiology, College of Medicine, University of Florida, Gainesville, FL, 32610, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing-Bo","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Beijing Aerospace General Hospital, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shih-Ting","family":"Tsao","sequence":"additional","affiliation":[{"name":"Department of Molecular Genetics and Microbiology, College of Medicine, University of Florida, Gainesville, FL, 32610, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuchen","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Molecular Genetics and Microbiology, College of Medicine, University of Florida, Gainesville, FL, 32610, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Molecular Genetics and Microbiology, College of Medicine, University of Florida, Gainesville, FL, 32610, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William B.","family":"Slayton","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Division of Hematology Oncology, College of Medicine, University of Florida, Gainesville, FL, 32610, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan S.","family":"Moreb","sequence":"additional","affiliation":[{"name":"Department of Medicine, College of Medicine, University of Florida, Gainesville, FL, 32610, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lujia","family":"Dong","sequence":"additional","affiliation":[{"name":"Geno-immune Medical Institute, Shenzhen, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lung-Ji","family":"Chang","sequence":"additional","affiliation":[{"name":"Geno-immune Medical Institute, Shenzhen, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1073\/pnas.90.2.720","volume":"90","author":"Eshhar Z.","year":"1993","unstructured":"Eshhar Z, Waks T, Gross G, Schindler DG.  Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors.","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=2","doi-asserted-by":"crossref","first-page":"10995","DOI":"10.1158\/0008-5472.CAN-06-0160","volume":"66","author":"Kowolik C.M.","year":"2006","unstructured":"Kowolik CM, Topp MS, Gonzalez S.  CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances  persistence and antitumor efficacy of adoptively transferred T cells.","journal-title":"Cancer Res"},{"key":"ref=3","first-page":"3369","volume":"55","author":"Hwu P.","year":"1995","unstructured":"Hwu P, Yang JC, Cowherd R.  \n antitumor activity of T cells redirected with chimeric antibody\/T-cell receptor genes.","journal-title":"Cancer Res"},{"key":"ref=4","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1172\/JCI46110","volume":"121","author":"Savoldo B.","year":"2011","unstructured":"Savoldo B, Ramos CA, Liu E.  CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients.","journal-title":"J Clin Invest"},{"key":"ref=5","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1158\/0008-5472.CAN-11-0422","volume":"71","author":"Song D.G.","year":"2011","unstructured":"Song DG, Ye Q, Carpenito C.  \n persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB).","journal-title":"Cancer Res"},{"key":"ref=6","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1073\/pnas.0813101106","volume":"106","author":"Carpenito C.","year":"2009","unstructured":"Carpenito C, Milone MC, Hassan R.  Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains.","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=7","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","volume":"365","author":"Porter D.L.","year":"2011","unstructured":"Porter DL, Levine BL, Kalos M, Bagg A, June CH.  Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia.","journal-title":"N Engl J Med"},{"key":"ref=8","doi-asserted-by":"crossref","first-page":"177ra138","DOI":"10.1126\/scitranslmed.3005930","volume":"5","author":"Brentjens R.J.","year":"2013","unstructured":"Brentjens RJ, Davila ML, Riviere I.  CD19-Targeted T Cells Rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia.","journal-title":"Sci Transl Med"},{"key":"ref=9","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","volume":"368","author":"Grupp S.A.","year":"2013","unstructured":"Grupp SA, Kalos M, Barrett D.  Chimeric antigen receptor-modified t cells for acute lymphoid leukemia.","journal-title":"N Engl J Med"},{"key":"ref=10","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1182\/blood-2013-06-506741","volume":"122","author":"Cruz C.R.","year":"2013","unstructured":"Cruz CR, Micklethwaite KP, Savoldo B.  Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: A phase 1 study.","journal-title":"Blood"},{"key":"ref=11","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1182\/blood-2011-04-348540","volume":"118","author":"Brentjens R.J.","year":"2011","unstructured":"Brentjens RJ, Riviere I, Park JH.  Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias.","journal-title":"Blood"},{"key":"ref=12","doi-asserted-by":"crossref","first-page":"4129","DOI":"10.1182\/blood-2013-08-519413","volume":"122","author":"Kochenderfer J.N.","year":"2013","unstructured":"Kochenderfer JN, Dudley ME, Carpenter RO.  Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation.","journal-title":"Blood"},{"key":"ref=13","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1182\/blood-2013-11-492231","volume":"123","author":"Maus M.V.","year":"2014","unstructured":"Maus MV, Grupp SA, Porter DL, June CH.  Antibody-modified T cells: CARs take the front seat for hematologic malignancies.","journal-title":"Blood"},{"key":"ref=14","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s12185-013-1490-x","volume":"99","author":"Turtle C.J.","year":"2014","unstructured":"Turtle CJ.  Chimeric antigen receptor modified T cell therapy for B cell malignancies.","journal-title":"Int J Hematol"},{"key":"ref=15","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.tips.2011.09.004","volume":"33","author":"Steel J.C.","year":"2012","unstructured":"Steel JC, Waldmann TA, Morris JC.  Interleukin-15 biology and its therapeutic implications in cancer.","journal-title":"Trends Pharmacol Sci"},{"key":"ref=16","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1006\/cimm.1995.1216","volume":"165","author":"Munger W.","year":"1995","unstructured":"Munger W, DeJoy SQ, Jeyaseelan R.  Studies evaluating the antitumor activity and toxicity of interleukin-15, a new T cell growth factor: Comparison with interleukin-2.","journal-title":"Cell Immunol"},{"key":"ref=17","doi-asserted-by":"crossref","first-page":"11445","DOI":"10.1073\/pnas.200363097","volume":"97","author":"Marks-Konczalik J.","year":"2000","unstructured":"Marks-Konczalik J, Dubois S, Losi JM.  IL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice.","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=18","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.cytogfr.2011.04.001","volume":"22","author":"Jakobisiak M.","year":"2011","unstructured":"Jakobisiak M, Golab J, Lasek W.  Interleukin 15 as a promising candidate for tumor immunotherapy.","journal-title":"Cytokine Growth Factor Rev"},{"key":"ref=19","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.cytogfr.2006.05.001","volume":"17","author":"Budagian V.","year":"2006","unstructured":"Budagian V, Bulanova E, Paus R, Bulfone-Paus S.  IL-15\/IL-15 receptor biology: A guided tour through an expanding universe.","journal-title":"Cytokine Growth Factor Rev"},{"key":"ref=20","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/icb.2014.103","volume":"93","author":"Okada S.","year":"2015","unstructured":"Okada S, Han S, Patel ES, Yang LJ, Chang LJ.  STAT3 signaling contributes to the high effector activities of interleukin-15-derived dendritic cells.","journal-title":"Immunol Cell Biol"},{"key":"ref=21","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1182\/bloodadvances.2018017004","volume":"2","author":"Zhang J.P.","year":"2018","unstructured":"Zhang JP, Zhang R, Tsao ST.  Sequential allogeneic and autologous CAR-T-cell therapy to treat an immune-compromised leukemic patient.","journal-title":"Blood Adv"},{"key":"ref=22","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1006\/viro.1995.1388","volume":"211","author":"Chang L-J.","year":"1995","unstructured":"Chang L-J, Zhang C.  Infection and replication of Tat-minus human immunodeficiency viruses: Genetic analyses of LTR and tat mutants in primary and long-term human lymphoid cells.","journal-title":"Virology"},{"key":"ref=23","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/sj.gt.3302509","volume":"12","author":"Chang L-J.","year":"2005","unstructured":"Chang L-J, Liu X, He J.  Lentiviral siRNAs targeting multiple highly conserved RNA sequences of human immunodeficiency virus type 1.","journal-title":"Gene Ther"},{"key":"ref=24","doi-asserted-by":"crossref","first-page":"3477","DOI":"10.1016\/j.vaccine.2006.02.025","volume":"24","author":"Wang B.","year":"2006","unstructured":"Wang B, He J, Liu C, Chang LJ.  An effective cancer vaccine modality: Lentiviral modification of dendritic cells expressing multiple cancer-specific antigens.","journal-title":"Vaccine"},{"key":"ref=25","doi-asserted-by":"crossref","first-page":"525","DOI":"10.2144\/97233pf01","volume":"23","author":"Zhang G.","year":"1997","unstructured":"Zhang G, Gurtu V, Kain SR, Yan G.  Early detection of apoptosis using a fluorescent conjugate of annexin V.","journal-title":"Biotechniques"},{"key":"ref=26","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S0161-5890(97)00144-2","volume":"34","author":"Nicholson I.C.","year":"1997","unstructured":"Nicholson IC, Lenton KA, Little DJ.  Construction and characterisation of a functional CD19 specific single chain Fv fragment for immunotherapy of B lineage leukaemia and lymphoma.","journal-title":"Mol Immunol"},{"key":"ref=27","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1097\/CJI.0b013e3181ac6138","volume":"32","author":"Kochenderfer J.N.","year":"2009","unstructured":"Kochenderfer JN, Feldman SA, Zhao Y.  Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor.","journal-title":"J Immunother"},{"key":"ref=28","first-page":"468","volume":"3","author":"Chang L-J.","year":"2001","unstructured":"Chang L-J, He J.  Retroviral vectors for gene therapy of AIDS and cancer.","journal-title":"Curr Opin Mol Ther"},{"key":"ref=29","first-page":"303","volume":"69","author":"Chang L.J.","year":"2002","unstructured":"Chang LJ, Zaiss AK.  Methods for the preparation and use of lentivirus vectors.","journal-title":"Methods Mol Med"},{"key":"ref=30","first-page":"181","volume":"14","author":"Brunner K.T.","year":"1968","unstructured":"Brunner KT, Mauel J, Cerottini JC, Chapuis B.  Quantitative assay of the lytic action of immune lymphoid cells on 51-Cr-labelled allogeneic target cells ; inhibition by isoantibody and by drugs.","journal-title":"Immunology"},{"key":"ref=31","doi-asserted-by":"crossref","first-page":"577","DOI":"10.2217\/imt.13.37","volume":"5","author":"Henderson M.A.","year":"2013","unstructured":"Henderson MA, Yong CS, Duong CP.  Chimeric antigen receptor-redirected T cells display multifunctional capacity and enhanced tumor-specific cytokine secretion upon secondary ligation of chimeric receptor.","journal-title":"Immunotherapy"},{"key":"ref=32","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/nri911","volume":"2","author":"Trapani J.A.","year":"2002","unstructured":"Trapani JA, Smyth MJ.  Functional significance of the perforin\/granzyme cell death pathway.","journal-title":"Nat Rev Immunol"},{"key":"ref=33","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0091-679X(04)75020-7","volume":"75","author":"Betts M.R.","year":"2004","unstructured":"Betts MR, Koup RA.  Detection of T-cell degranulation: CD107a and b.","journal-title":"Methods Cell Biol"},{"key":"ref=34","doi-asserted-by":"crossref","first-page":"6738","DOI":"10.4049\/jimmunol.181.10.6738","volume":"181","author":"Kinter A.L.","year":"2008","unstructured":"Kinter AL, Godbout EJ, McNally JP.  The common gamma-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands.","journal-title":"J Immunol"},{"key":"ref=35","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1097\/CJI.0000000000000001","volume":"36","author":"Tao Q.","year":"2013","unstructured":"Tao Q, Chen T, Tao L.  IL-15 improves the cytotoxicity of cytokine-induced killer cells against leukemia cells by upregulating CD3+CD56+ cells and downregulating regulatory T cells as well as IL-35.","journal-title":"J Immunother"},{"key":"ref=36","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1038\/leu.2010.75","volume":"24","author":"Hoyos V.","year":"2010","unstructured":"Hoyos V, Savoldo B, Quintarelli C.  Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma\/leukemia effects and safety.","journal-title":"Leukemia"},{"key":"ref=37","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.ccr.2012.09.009","volume":"22","author":"Mishra A.","year":"2012","unstructured":"Mishra A, Liu S, Sams GH.  Aberrant overexpression of IL-15 initiates large granular lymphocyte leukemia through chromosomal instability and DNA hypermethylation.","journal-title":"Cancer Cell"},{"key":"ref=38","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.1182\/blood-2013-05-499970","volume":"123","author":"Williams M.T.","year":"2014","unstructured":"Williams MT, Yousafzai Y, Cox C.  Interleukin-15 enhances cellular proliferation and upregulates CNS homing molecules in pre-B acute lymphoblastic leukemia.","journal-title":"Blood"},{"key":"ref=39","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1586\/eci.13.28","volume":"9","author":"Steinway S.N.","year":"2013","unstructured":"Steinway SN, Loughran TP.  Targeting IL-15 in large granular lymphocyte leukemia.","journal-title":"Expert Rev Clin Immunol"}],"container-title":["Current Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/167421","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T19:35:47Z","timestamp":1569958547000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/167421\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,28]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,5,28]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1566523218666181116093857","relation":{},"ISSN":["1566-5232"],"issn-type":[{"value":"1566-5232","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5,28]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2018-09-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-11-12","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-11-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-05-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}